Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
暂无分享,去创建一个
T. Yamanaka | I. Hyodo | K. Muro | N. Boku | A. Hosokawa | T. Moriwaki | J. Kawada | S. Hironaka | H. Yasui | Y. Sukawa | A. Tsuji | K. Yamazaki | K. Nishikawa | T. Esaki | H. Tsukuda | K. Shinozaki | Y. Horie | A. Makiyama | K. Uchino | H. Tanioka | T. Kashiwada | H. Ishida | Hiroyasu Ishida
[1] E. Oki,et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). , 2018, European journal of cancer.
[2] G. Lee,et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) , 2018, Gastric Cancer.
[3] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[4] G. Giaccone,et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] N. Sugimoto,et al. Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G) , 2017, Gastric Cancer.
[6] H. Miyata,et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] K. Masuda,et al. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer , 2016, Gastric Cancer.
[8] F. Akiyama,et al. Trastuzumab Rechallenge After Lapatinib- and Trastuzumab-Resistant Disease Progression in HER2-Positive Breast Cancer. , 2015, Clinical breast cancer.
[9] G. Minuti,et al. Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. , 2015, The oncologist.
[10] M. Dieci,et al. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] Yaohui Wang,et al. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis , 2013, Current medical research and opinion.
[12] A. Jimeno,et al. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] M. J. van de Vijver,et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.
[14] J. Baselga,et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. , 2007, Journal of the National Cancer Institute.